Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALC Alcon	$94.94 +0.3%	$90.84	$77.54 ▼ $101.10	$46.83B	0.99	1.04 million shs	665,024 shs
INO Inovio Pharmaceuticals	$1.87 -2.6%	$1.85	$1.42 ▼ $13.44	$68.57M	1.84	578,768 shs	262,789 shs
SNN Smith & Nephew	$26.65 -1.3%	$27.50	$23.69 ▼ $31.72	$11.67B	0.71	828,298 shs	928,869 shs
STE STERIS	$225.00 -0.6%	$222.78	$200.41 ▼ $248.24	$22.11B	0.87	524,787 shs	368,819 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALC Alcon	+0.99%	+2.35%	+2.06%	+6.32%	+19.00%
INO Inovio Pharmaceuticals	+2.67%	+10.34%	+6.08%	-11.93%	-81.10%
SNN Smith & Nephew	+1.73%	+4.26%	-5.06%	+7.62%	+9.89%
STE STERIS	+0.96%	+1.78%	+2.22%	+4.43%	+11.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALC Alcon	2.8518 of 5 stars	3.4	3.0	1.7	0.0	2.2	0.8	1.3
INO Inovio Pharmaceuticals	3.382 of 5 stars	3.3	1.0	0.0	4.3	2.0	0.0	1.3
SNN Smith & Nephew	2.494 of 5 stars	1.0	4.0	2.5	0.0	3.2	0.0	3.1
STE STERIS	4.6327 of 5 stars	2.4	5.0	4.2	3.8	3.7	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALC Alcon	2.71	Moderate Buy	$106.22	11.88% Upside
INO Inovio Pharmaceuticals	2.60	Moderate Buy	$12.20	552.41% Upside
SNN Smith & Nephew	2.00	Hold	$27.00	1.31% Upside
STE STERIS	2.80	Moderate Buy	$258.75	15.00% Upside

Current Analyst Ratings Breakdown

Latest STE, INO, SNN, and ALC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/25/2025	SNN Smith & Nephew	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
4/10/2025	STE STERIS	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$265.00 ➝ $265.00
4/7/2025	STE STERIS	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/31/2025	ALC Alcon	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$108.00 ➝ $112.00
3/28/2025	ALC Alcon	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$115.00 ➝ $120.00
3/28/2025	ALC Alcon	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$107.00 ➝ $110.00
3/25/2025	ALC Alcon	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
3/25/2025	ALC Alcon	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/25/2025	ALC Alcon	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy
3/20/2025	ALC Alcon	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$107.00 ➝ $107.00
3/19/2025	INO Inovio Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$6.00 ➝ $5.00

(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALC Alcon	$9.91B	4.72	$5.51 per share	17.23	$41.81 per share	2.27
INO Inovio Pharmaceuticals	$217.76K	314.88	N/A	N/A	$5.16 per share	0.36
SNN Smith & Nephew	$5.81B	2.01	$3.33 per share	8.00	$11.94 per share	2.23
STE STERIS	$5.40B	4.10	$14.30 per share	15.73	$65.43 per share	3.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALC Alcon	$974M	$2.05	40.57	28.86	2.29	11.89%	7.17%	5.03%	5/13/2025 (Estimated)
INO Inovio Pharmaceuticals	-$135.12M	-$3.99	N/A	N/A	N/A	N/A	-118.17%	-83.47%	5/12/2025 (Estimated)
SNN Smith & Nephew	$263M	$2.16	12.34	13.33	1.26	N/A	N/A	N/A	N/A
STE STERIS	$378.24M	$4.71	47.77	22.66	N/A	8.66%	13.91%	8.64%	5/6/2025 (Estimated)

Latest STE, INO, SNN, and ALC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q4 2025	STE STERIS	$2.58	N/A	N/A	N/A	$1.47 billion	N/A
5/13/2025	Q1 2025	ALC Alcon	$0.76	N/A	N/A	N/A	$2.52 billion	N/A
5/12/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	N/A	N/A	N/A	$0.01 million	N/A
3/18/2025	Q4 2024	INO Inovio Pharmaceuticals	-$0.87	-$0.69	+$0.18	-$0.60	$0.03 million	$0.12 million
2/25/2025	Q4 2024	ALC Alcon	$0.70	$0.72	+$0.02	$0.57	$2.47 billion	$2.48 billion
2/5/2025	Q3 2025	STE STERIS	$2.33	$2.32	-$0.01	$1.75	$1.38 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALC Alcon	$0.26	0.27%	+33.89%	12.68%	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SNN Smith & Nephew	$0.89	3.34%	N/A	41.20%	N/A
STE STERIS	$2.28	1.01%	+9.51%	48.41%	20 Years

Latest STE, INO, SNN, and ALC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/26/2025	SNN Smith & Nephew	semi-annual	$0.4470	2.5%	3/28/2025	3/28/2025	5/28/2025
4/7/2025	ALC Alcon	annual	$0.3270	0.3%	5/14/2025	5/14/2025	5/15/2025
1/28/2025	STE STERIS	quarterly	$0.57	1.03%	2/20/2025	2/20/2025	3/21/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALC Alcon	0.21	2.57	1.60
INO Inovio Pharmaceuticals	N/A	3.88	3.88
SNN Smith & Nephew	0.63	2.51	1.11
STE STERIS	0.32	2.13	1.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALC Alcon	53.86%
INO Inovio Pharmaceuticals	26.79%
SNN Smith & Nephew	25.64%
STE STERIS	94.69%

Insider Ownership

Company	Insider Ownership
ALC Alcon	1.52%
INO Inovio Pharmaceuticals	2.50%
SNN Smith & Nephew	1.00%
STE STERIS	1.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALC Alcon	25,200	493.24 million	N/A	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	25.45 million	Optionable
SNN Smith & Nephew	20,100	437.96 million	432.83 million	Optionable
STE STERIS	16,000	98.25 million	97.13 million	Optionable

STE, INO, SNN, and ALC Headlines

Recent News About These Companies

Commerce Bank Purchases 1,300 Shares of STERIS plc (NYSE:STE)

April 24 at 4:52 AM | marketbeat.com

Kayne Anderson Rudnick Investment Management LLC Acquires 7,285 Shares of STERIS plc (NYSE:STE)

April 23 at 6:02 AM | marketbeat.com

Curi RMB Capital LLC Reduces Holdings in STERIS plc (NYSE:STE)

April 23 at 5:16 AM | marketbeat.com

Jump Financial LLC Makes New $993,000 Investment in STERIS plc (NYSE:STE)

April 23 at 4:27 AM | marketbeat.com

STERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025

April 22 at 4:30 PM | globenewswire.com

Thematics Asset Management Has $38.97 Million Position in STERIS plc (NYSE:STE)

April 22 at 6:54 AM | marketbeat.com

Norinchukin Bank The Has $21.76 Million Stock Position in STERIS plc (NYSE:STE)

April 21, 2025 | marketbeat.com

Marshall Wace LLP Sells 347,615 Shares of STERIS plc (NYSE:STE)

April 21, 2025 | marketbeat.com

Bridgewater Associates LP Has $2.26 Million Stake in STERIS plc (NYSE:STE)

April 21, 2025 | marketbeat.com

Barclays PLC Acquires 31,497 Shares of STERIS plc (NYSE:STE)

April 21, 2025 | marketbeat.com

Allred Capital Management LLC Acquires Shares of 2,732 STERIS plc (NYSE:STE)

April 20, 2025 | marketbeat.com

CANADA LIFE ASSURANCE Co Decreases Position in STERIS plc (NYSE:STE)

April 19, 2025 | marketbeat.com

STERIS plc (NYSE:STE) Shares Bought by Champlain Investment Partners LLC

April 19, 2025 | marketbeat.com

United Capital Financial Advisors LLC Has $9.06 Million Stock Position in STERIS plc (NYSE:STE)

April 18, 2025 | marketbeat.com

Sterling Capital Management LLC Buys 2,084 Shares of STERIS plc (NYSE:STE)

April 18, 2025 | marketbeat.com

Advisors Capital Management LLC Trims Stake in STERIS plc (NYSE:STE)

April 17, 2025 | marketbeat.com

STERIS plc (NYSE:STE) Holdings Boosted by Townsquare Capital LLC

April 17, 2025 | marketbeat.com

Is it the Right Time to Hold STERIS Stock in Your Portfolio?

April 16, 2025 | zacks.com

Sagespring Wealth Partners LLC Purchases Shares of 4,677 STERIS plc (NYSE:STE)

April 16, 2025 | marketbeat.com

Qtron Investments LLC Takes Position in STERIS plc (NYSE:STE)

April 16, 2025 | marketbeat.com

STERIS plc (NYSE:STE) Shares Purchased by Rockefeller Capital Management L.P.

April 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVIDIA vs Qualcomm: Which Is the Better Buy for Q2?
By Sam Quirke | April 3, 2025
View NVIDIA vs Qualcomm: Which Is the Better Buy for Q2?
2 Smart Investments to Follow Warren Buffett’s Lead
By Ryan Hasson | April 23, 2025
View 2 Smart Investments to Follow Warren Buffett’s Lead
4 Dividend Growth Stocks the Trade Tariffs Can’t Touch
By Thomas Hughes | April 7, 2025
View 4 Dividend Growth Stocks the Trade Tariffs Can’t Touch
Amazon Stock Bounces From Lows as Smart Money Steps In
By Sam Quirke | April 9, 2025
View Amazon Stock Bounces From Lows as Smart Money Steps In
PayPal Stock: Too Cheap to Ignore, Too Strong to Miss
By Jea Yu | April 8, 2025
View PayPal Stock: Too Cheap to Ignore, Too Strong to Miss

STE, INO, SNN, and ALC Company Descriptions

Alcon NYSE:ALC

$94.94 +0.26 (+0.27%)

Closing price 03:59 PM Eastern

Extended Trading

$94.92 -0.02 (-0.03%)

As of 05:40 PM Eastern

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Inovio Pharmaceuticals NASDAQ:INO

$1.87 -0.05 (-2.60%)

Closing price 04:00 PM Eastern

Extended Trading

$1.88 +0.01 (+0.53%)

As of 05:55 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Smith & Nephew NYSE:SNN

$26.65 -0.35 (-1.30%)

Closing price 03:59 PM Eastern

Extended Trading

$26.64 -0.01 (-0.06%)

As of 04:26 PM Eastern

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

STERIS NYSE:STE

$225.00 -1.35 (-0.60%)

Closing price 03:59 PM Eastern

Extended Trading

$224.86 -0.13 (-0.06%)

As of 04:41 PM Eastern

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time